PTC Therapeutics Inc [PTCT] stock is trading at $48.89, up 3.41%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PTCT shares have gain 5.80% over the last week, with a monthly amount drifted -1.27%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on May 09, 2025, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $68 for it. Previously, Citigroup upgraded its rating to Neutral on May 07, 2025, and kept the price target unchanged to $40. On March 11, 2025, upgrade upgraded it’s rating to Neutral and revised its price target to $55 on the stock. Scotiabank started tracking the stock assigning a Sector Perform rating and suggested a price target of $55 on March 07, 2025. Morgan Stanley upgraded its rating to a Overweight and raised its price target to $67 on December 13, 2024. RBC Capital Mkts upgraded its rating to Outperform for this stock on December 03, 2024, and upped its price target to $63.
PTC Therapeutics Inc [PTCT] stock has fluctuated between $28.72 and $58.38 over the past year. Currently, Wall Street analysts expect the stock to reach $62 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $48.89 at the most recent close of the market. An investor can expect a potential return of 26.82% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
PTC Therapeutics Inc [NASDAQ:PTCT] reported sales of 1.77B for the trailing twelve months, which represents a growth of 459.73%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at 0.41%, Pretax Profit Margin comes in at 0.37%, and Net Profit Margin reading is 0.34%. To continue investigating profitability, this company’s Return on Assets is posted at 0.22, Equity is -0.72 and Total Capital is 0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 47.90 points at the first support level, and at 46.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 49.51, and for the 2nd resistance point, it is at 50.14.
Ratios To Look Out For
For context, PTC Therapeutics Inc’s Current Ratio is 3.89. Further, the Quick Ratio stands at 3.85, while the Cash Ratio is 2.49. Considering the valuation of this stock, the price to sales ratio is 2.19 and price to earnings (TTM) ratio is 7.51.
Transactions by insiders
Recent insider trading involved Boulding Mark Elliott, EXEC. VP AND CLO, that happened on May 15 ’25 when 1929.0 shares were sold. EXEC. VP AND CLO, Boulding Mark Elliott completed a deal on May 16 ’25 to sell 883.0 shares. Meanwhile, Officer Boulding Mark Elliott bought 883.0 shares on May 16 ’25.
